Health Affairs, 25, no. 5 (2006): 1240-1248
doi: 10.1377/hlthaff.25.5.1240
© 2006 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Bowman, J.
* Articles by Harrison, C.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Bowman, J.
* Articles by Harrison, C.
Related Collections
* Access To Care
* Insurance Coverage
* Managed Care - Medicare
* Medicare
* Business Of Health
* Pharmaceuticals
* Research And Technology
* Health Spending
* Consumer Issues
* Insurance Market
* Evidence-Based Medicine

Coverage

Access To Cancer Drugs In Medicare Part D: Formulary Placement And Beneficiary Cost Sharing In 2006

Jennifer Bowman, Amy Rousseau, David Silk and Catherine Harrison

The Medicare Part D benefit expands the universe of cancer drugs and biologics that Medicare may cover. Individual Part D plans have discretion to determine their formularies and cost sharing for drugs within federal guidelines. This paper analyzes differences in coverage and cost sharing for cancer drugs among these plans. We find that many cancer drugs, including brand-name products, are covered by almost all plans, although prior authorization might limit access to some. In addition, many plans charge a relatively low copayment for most cancer drugs. These findings suggest that Part D could greatly expand beneficiaries’ access to cancer treatments.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
NEJMHome page
P. B. Bach
Limits on Medicare's Ability to Control Rising Spending on Cancer Drugs
N. Engl. J. Med., February 5, 2009; 360(6): 626 - 633.
[Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
P. Neuman, M. K. Strollo, S. Guterman, W. H. Rogers, A. Li, A. M. C. Rodday, and D. G. Safran
Medicare Prescription Drug Benefit Progress Report: Findings From A 2006 National Survey Of Seniors
Health Aff., September 1, 2007; 26(5): w630 - w643.
[Abstract] [Full Text] [PDF]